Lv41
470 积分 2022-06-01 加入
TRANSCAR: Real-World outcomes of CD19CAR T Cell Therapy in relapsed/refractory transformed indolent lymphomas
2个月前
已关闭
Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
2个月前
已关闭
中国临床肿瘤学会（CSCO）淋巴瘤专家委员会. T细胞免疫疗法治疗侵袭性B细胞淋巴瘤中国专家共识（2025年版）
3个月前
已完结
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
6个月前
已完结
Preliminary efficacy and safety of Relmacabtagene autoleucel (Carteyva) in adults with relapsed/refractory follicular lymphoma in China: A phase I/II clinical trial
6个月前
已完结
CAR T‐cell therapy in large B cell lymphoma
8个月前
已完结
Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma
8个月前
已完结
CAR T-cell therapy for B-cell lymphoma
8个月前
已完结
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
8个月前
已完结
皖公网安备34019202002308
